Journal List > Korean J Urol > v.50(10) > 1005224

Kim, Kim, and Kim: Crystal Deposits on Renal Papillae in Stone Formers

Abstract

Purpose

Papillary “Randall’s plaques” are theorized to act as nidi for urinary stone formation. In this study, we used endoscopic examination and intraoperative biopsy of renal papilla in stone formers undergoing percutaneous nephrolithotomy (PNL) to investigate the correlation between Randall’s papillary plaque and primary stone composition and metabolic risk factors.

Materials and Methods

A total of 34 patients with renal stones were enrolled. During PNL performed for stone removal, biopsy specimens were taken from selected papilla. We evaluated constituents such as volume, sodium, uric acid, calcium, oxalate, and citrate from 24-hour urine samples, and calcium, sodium, uric acid, phosphate, potassium, and chloride from serum samples 1 month after PNL.

Results

We identified Randall’s plaque in 26 patients as irregular, whitish lesions, generally located on the papillary tip. We performed intraoperative biopsies of papilla in the kidneys of stone formers and of known regions of crystal deposits in the interstitial tissue surrounding the ducts. There was no correlation between serum variables, 24-hour urine constituents, and presence of plaque. However, 24-hour urine volume was negatively correlated with the presence of plaque. The incidence of papillary plaques varied with the primary composition of extracted stones and was 80% for calcium oxalate, 92% for calcium phosphate, 50% for uric acid, and 25% for struvite stones (p=0.035).

Conclusions

The incidence of papillary Randall’s plaques in patients with nephrolithiasis varied with the primary composition of formed urinary stones. Randall’s plaques are found in most patients with calcium stones. Our findings suggest that the presence of papillary plaque is associated with calcium nephrolithiasis and may contribute to the pathogenesis, treatment, and prevention of calcium urinary stones.

REFERENCES

1.Porena M., Guiggi P., Micheli C. Prevention of stone disease. Urol Int. 2007. 79(Suppl 1):37–46.
crossref
2.Bartoletti R., Cai T., Mondaini N., Melone F., Travaglini F., Carini M, et al. Epidemiology and risk factors in urolithiasis. Urol Int. 2007. 79(Suppl 1):3–7.
crossref
3.Pearle MS., Calhoun EA., Curhan GC. Urologic diseases in America project: urolithiasis. J Urol. 2005. 173:848–57.
crossref
4.Randall A. The origin and growth of renal calculi. Ann Surg. 1937. 105:1009–27.
crossref
5.Matlaga BR., Williams JC Jr., Kim SC., Kuo RL., Evan AP., Bledsoe SB, et al. Endoscopic evidence of calculus attachment to Randall's plaque. J Urol. 2006. 175:1720–4.
crossref
6.Low RK., Stoller ML. Endoscopic mapping of renal papillae for Randall's plaques in patients with urinary stone disease. J Urol. 1997. 158:2062–4.
crossref
7.Indridason OS., Birgisson S., Edvardsson VO., Sigvaldason H., Sigfusson N., Palsson R. Epidemiology of kidney stones in Iceland: a population-based study. Scand J Urol Nephrol. 2006. 40:215–20.
crossref
8.Ramello A., Vitale C., Marangella M. Epidemiology of nephrolithiasis. J Nephrol. 2000. 13(Suppl 3):S45–50.
9.Trinchieri A., Coppi F., Montanari E., Del Nero A., Zanetti G., Pisani E. Increase in the prevalence of symptomatic upper urinary tract stones during the last ten years. Eur Urol. 2000. 37:23–5.
crossref
10.Ye SJ., Yoo ES., Park YK. Analysis of urinary stone components during the last two decades. Korean J Urol. 2007. 48:1285–8.
crossref
11.Jun IO., Moon YT. Comparison of stone metabolic risk factors in recurrent stone formers according to sex and age. Korean J Urol. 2002. 43:733–7.
12.Kim SD., Yang WJ., Chung JY. Recurrence rate and risk factors for stone recurrence after successful extracorporeal shock wave lithotripsy: 5-year-follow-up study. Korean J Urol. 2007. 48:49–53.
crossref
13.Abe T., Akakura K., Kawaguchi M., Ueda T., Ichikawa T., Ito H, et al. Outcomes of shockwave lithotripsy for upper urinary-tract stones: a large-scale study at a single institution. J Endourol. 2005. 19:768–73.
crossref
14.Netelenbos JC., Zwijnenburg PJ., ter Wee PM. Risk factors determining active urinary stone formation in patients with urolithiasis. Clin Nephrol. 2005. 63:188–92.
crossref
15.DeFoor W., Minevich E., Jackson E., Reddy P., Clark C., Sheldon C, et al. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol. 2008. 179:2369–72.
crossref
16.Robinson MR., Leitao VA., Haleblian GE., Scales CD Jr., Chandrashekar A., Pierre SA, et al. Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. J Urol. 2009. 181:1145–50.
crossref
17.Cha JS., Jeon SB., Kim MK., Jeong YB., Kim YG. Metabolic stone risk factors associated with papillary calcification on unenhanced spiral computed tomography. Korean J Urol. 2006. 47:507–11.
crossref
18.Kuo RL., Lingeman JE., Evan AP., Paterson RF., Parks JH., Bledsoe SB, et al. Urine calcium and volume predict coverage of renal papilla by Randall's plaque. Kidney Int. 2003. 64:2150–4.
crossref
19.Evan AP., Lingeman JE., Coe FL., Parks JH., Bledsoe SB., Shao Y, et al. Randall's plaque or patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest. 2003. 111:607–16.
20.Miller NL., Gillen DL., Williams JC Jr., Evan AP., Bledose SB., Coe FL, et al. A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall's plaque. BJU Int. 2009. 103:966–71.
crossref
21.Cifuentes Delatte L., Miñón-Cifuentes J., Medina JA. New studies on papillary calculi. J Urol. 1987. 137:1024–9.
22.Low RK., Stoller ML., Schreiber CK. Metabolic and urinary risk factors associated with Randall's papillary plaques. J Endourol. 2000. 14:507–10.
crossref

Fig. 1.
Endoscopic and histologic images of Randall’s plaques in stone formers. In (A), an example of a papilla from a stone former that was videotaped at the time of the mapping is shown. Several sites of Randall’s plaque (arrows) appear as irregular white areas beneath the urothelium. In addition, a plaque site was noted that lacked a urothelial layer and was thought to be a site where a stone had been attached to the side of the papilla (arrows). In (B), a low-magnification light-microscopic image of a papillary biopsy specimen from a patient is shown; the sites of calcium deposits are indicated with arrows. (C) A light micrograph shows large regions of crystal deposits in the interstitial tissue surrounding the ducts (arrows). H&E stain, magnification, x100 (B); x400 (C).
kju-50-1009f1.tif
Table 1.
Results of serum analysis for the patients with and without papillary plaque
Group I (n=24) Group II (n=8) p-value
Sodium (mEq/l) 141.33±2.97 140.63±3.07 >0.5
Potassium (mEq/l) 4.19±0.49 4.42±0.65 >0.3
Chloride (mEq/l) 104.38±3.09 105.13±2.42 >0.5
BUN (mg/dl) 17.13±7.16 17.50±3.89 >0.8
Creatinine (mg/dl) 0.97±0.31 1.11±0.60 >0.4
Uric acid (mg/dl) 5.71±1.81 5.28±1.03 >0.5
Total calcium (mg/dl) 9.45±0.76 9.35±0.55 >0.7
Triglyceride (mg/dl) 120.40±89.37 77.00±59.25 >0.4
PTH (pg/ml) 70.97±42.65 52.91±43.29 >0.1

BUN: blood urea nitrogen, PTH: parathyroid hormone. Values are Mean±SD. ANOVA was used.

Table 2.
Results of 24-hour urine analysis for the patients with and without papillary plaque
Group I (n=10) Group II (n=6) p-value
Urine volume (ml/day) 1,459.00±587.21 2,300.00±437.04 0.009
Sodium (mEq/day) 217.00±165.56 277.00±64.0 >0.4
Potassium (mEq/day) 43.74±23.99 64.17±23.23 >0.1
Chloride (mEq/day) 212.22±179.20 287.33±59.36 >0.3
Creatinine (mg/day) 1,157.50±441.90 1,152.50±181.77 >0.9
Calcium (mg/day) 235.67±134.16 217.67±159.49 >0.8
Phosphorus (mg/day) 590.78±252.03 780.00±384.32 >0.2
Uric acid (mg/day) 624.67±239.89 746.17±344.09 >0.4
Citric acid (mg/day) 340.53±214.75 409.60±263.32 >0.6
Oxalate (mg/day) 37.61±21.20 42.01±7.47 >0.6

Values are Mean±SD. ANOVA was used.

Table 3.
Incidence of papillary calcification relative to primary stone composition of extracted stones
Papillary calcification Primary stone composition
CaOx CaP UA Str p-value
Positive (n=26) 9/15 (80%) 12/13 (92%) 1/2 (50%) 1/4 (25%) 0.035
Negative (n=8) 3/15 (20%) 1/13 (8%) 1/2 (50%) 3/4 (75%)

CaOx: calcium oxalate, CaP: calcium phosphate, UA: uric acid, Str: struvite. Values are Mean±SD. Chi-square test was used.

TOOLS
Similar articles